Aura Biosciences, Inc. 8-K

What Happened

• Aura Biosciences (AURA) increased its board from six to seven members and appointed Jeremy Bender, Ph.D., M.B.A., as a Class II, independent director effective July 7, 2026. His term expires at the company’s 2029 annual meeting. Dr. Bender was also named to the Compensation Committee and the Nominating and Corporate Governance Committee.
• The company confirmed Dr. Bender will receive the same cash retainers as other non‑employee directors and entered into its standard indemnification agreement. As an initial equity grant he received a one‑time stock option for 60,000 shares and 30,000 restricted stock units (RSUs), vesting in equal annual installments over three years.

Key Details

• Board change: size increased from 6 to 7; appointment effective July 7, 2026; term ends at 2029 annual meeting.
• Initial equity for new directors: 60,000 stock options + 30,000 RSUs; vesting annually over 3 years; generally stop vesting if director leaves. Initial awards subject to an $800,000 aggregate cap (prorated if exceeded).
• Amended Non‑Employee Director Compensation Policy (effective June 11, 2026) sets cash retainers: Board members $40,000; non‑executive chair $30,000. Committee retainers: Audit members $10,000 (chair $20,000), Compensation members $7,500 (chair $15,000), Nominating/Governance members $5,000 (chair $10,000).
• Annual equity awards for continuing non‑employee directors increased to 30,000 option shares and 15,000 RSUs (annual award cap $400,000). Awards accelerate on a sale of the company.

Why It Matters

• Governance: A new independent director and committee appointments can affect oversight and strategy; investors should note the board expansion and committee composition changes.
• Compensation and dilution: The amended policy increases both cash and equity pay for non‑employee directors and raises initial and annual equity grant sizes, which could modestly increase share‑based compensation expense and potential dilution over time.
• No related‑party transactions were reported in connection with the appointment; Dr. Bender has no disclosed family ties or arrangements requiring additional disclosure.